Please assess the completion status of the following clinical trial:

Trial Title: ASTIC Autologous Stem Cell Transplantation for Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria: mandatory~1. Age between 18 and 50 years (Patients aged 50-65 can participate if specially approved by the Trial Steering Committee)~2. Confirmed diagnosis of active Crohn's Disease~3. Unsatisfactory course despite 3 immunosuppressive agents (usually azathioprine, methotrexate and infliximab) in addition to corticosteroids. Patients should have relapsing disease (i.e. \>1 exacerbation/year) despite thiopurines, methotrexate and/or infliximab maintenance therapy or clear demonstration of intolerance / toxicity to these drugs.~4. Impaired function and quality of life, compared to population means, on at least one of the following:~   1. IBDQ (Appendix 6)~  2. European Questionnaire of Life quality (EuroQOL-5D, Appendix 4)~  3. Impaired function on Karnofsky index (Appendix 7)~5. Current problems unsuitable for surgery and patient at risk for developing short bowel syndrome.~6. Informed consent~Inclusion criteria: discretionary~1. Wherever possible, diseased tissue should be accessible endoscopically for objective histological study but in the case of small bowel disease that is extensive but does not extend to duodenum or terminal ileum, participation without endoscopy is allowed.~2. Smokers may enter the study provided they have received intensive counselling about smoking.~3. Add patients with ileostomy/colostomy and patients with short bowel syndrome~Exclusion Criteria:~1. Pregnancy or unwillingness to use adequate contraception during the study~2. Concomitant severe disease~3. Diarrhoea due to short small or large bowel~4. Infection or risk thereof~5. Significant malnutrition: Body Mass Index (BMI) ≤18, serum albumin \<20 g/l~6. Previous poor compliance~7. Concurrent enrolment in any other protocol using an investigational drug or hematopoietic growth factor up to four weeks before study entry.~8. Lack of funding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant Arm (Type: EXPERIMENTAL): Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
- Delayed Transplant (Type: EXPERIMENTAL): Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).